4.6 Article

Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry

期刊

EUROPACE
卷 24, 期 5, 页码 721-728

出版社

OXFORD UNIV PRESS
DOI: 10.1093/europace/euab280

关键词

Atrial fibrillation; 4S-AF; Characterization; Classification; EORP-AF registry; Validation; Prognostic implications; Mortality; Thromboembolism; Stroke; Bleeding

资金

  1. Abbott Vascular Int
  2. Amgen Cardiovascular
  3. AstraZeneca
  4. Bayer
  5. Boehringer Ingelheim
  6. Boston Scientific
  7. Bristol Myers Squibb
  8. Alliance Daiichi Sankyo Europe GmbH
  9. Eli Lilly and Company
  10. Edwards [2016-19]
  11. Gedeon Richter Plc.
  12. Menarini Int. Op.
  13. MSD-Merck Co.
  14. Novartis Pharma AG
  15. ResMed
  16. Sanofi
  17. SERVIER
  18. Vifor
  19. Pfizer Alliance

向作者/读者索取更多资源

The 4S-AF classification scheme, consisting of four domains, including stroke risk, symptom severity, AF burden, and substrate, improves mortality rates in AF patients through treatment decisions. Implementing this scheme is feasible and associated with a significant decrease in all-cause mortality.
Aims The 4S-AF classification scheme comprises of four domains: stroke risk (St), symptoms (Sy), severity of atrial fibrillation (AF) burden (Sb), and substrate (Su). We sought to examine the implementation of the 4S-AF scheme in the EORP-AF General Long-Term Registry and compare outcomes in AF patients according to the 4S-AF-led decision-making process. Methods and results Atrial fibrillation patients from 250 centres across 27 European countries were included. A 4S-AF score was calculated as the sum of each domain with a maximum score of 9. Of 6321 patients, 8.4% had low (St), 47.5% EHRA I (Sy), 40.5% newly diagnosed or paroxysmal AF (Sb), and 5.1% no cardiovascular risk factors or left atrial enlargement (Su). Median follow-up was 24 months. Using multivariable Cox regression analysis, independent predictors of all-cause mortality were (St) [adjusted hazard ratio (aHR) 8.21, 95% confidence interval (CI): 2.60-25.9], (Sb) (aHR 1.21, 95% CI: 1.08-1.35), and (Su) (aHR 1.27, 95% CI: 1.14-1.41). For CV mortality and any thromboembolic event, only (Su) (aHR 1.73, 95% CI: 1.45-2.06) and (Sy) (aHR 1.29, 95% CI: 1.00-1.66) were statistically significant, respectively. None of the domains were independently linked to ischaemic stroke or major bleeding. Higher 4S-AF score was related to a significant increase in all-cause mortality, CV mortality, any thromboembolic event, and ischaemic stroke but not major bleeding. Treatment of all 4S-AF domains was associated with an independent decrease in all-cause mortality (aHR 0.71, 95% CI: 0.55-0.92). For each 4S-AF domain left untreated, the risk of all-cause mortality increased substantially (aHR 1.35, 95% CI: 1.16-1.56). Conclusion Implementation of the novel 4S-AF scheme is feasible, and treatment decisions based on this scheme improve mortality rates in AF.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据